The objective of the study is to evaluate the feasibility and interest of a HIV quarterly preventive global care for men who have sex with men (MSM) in sub-Saharan Africa to help reducing HIV incidence in this key population, their female partners, and the general population. This interventional, open label, multicenter, multidisciplinary cohort study will be conducted in Burkina Faso, Ivory Coast, Mali and Togo. All participants will receive a HIV quarterly preventive global care including: i) data collection on health status, symptoms of sexually transmitted infections (STI) and sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv) counselling adapted for MSM, and v) the provision of condoms and lubricants.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of people followed after 3 years compared to the number of persons included (retention in the program)
Timeframe: 3 years
Percentage of performed visits/scheduled visits
Timeframe: 3 years
Percentage of performed tests/scheduled tests
Timeframe: 3 years
Incidence of sexually transmitted infections
Timeframe: 3 years
Number of unprotected anal sex
Timeframe: 3 years
Antiretroviral therapy initiation probability in HIV-positive MSM
Timeframe: 3 years
Antiretroviral therapy maintenance probability in HIV-positive MSM
Timeframe: 3 years
Percentage of antiretroviral therapy observance in HIV-positive MSM
Timeframe: 3 years
Percentage of HIV-positive MSM with viral load>1000 copies/mL
Timeframe: 3 years
Percentage of HIV-positive MSM with CD4≤reference (or CD4<100/mm3)
Timeframe: 3 years
Percentage of HIV-positive MSM with new or recurrent AIDS-defining events (clinical stage 4)
Timeframe: 3 years
Percentage of HIV-positive MSM died under antiretroviral therapy
Timeframe: 3 years
Percentage of HIV-positive MSM with detectable viral load and inconsistent condom use with a partner seronegative or with unknown HIV status
Timeframe: 3 years
Number of HIV subtypes / circulating recombinant forms
Timeframe: 3 years
Number of co-infections with several viral variants
Timeframe: 3 years
Number of transmitted and acquired resistance mutations
Timeframe: 3 years
Number of male sex partners
Timeframe: 3 years